Inovio Pharmaceuticals Inc. (NASDAQ:INO) saw an upside of 1.93% to $0.45 after adding $0.01 on Tuesday. The 5-day average trading volume is 1,609,824 shares of the company’s common stock. It has gained $0.4600 in the past week and touched a new high 4 times within the past 5 days. An average of 2,279,091 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 7,763,949.
INO’s 1-month performance is -10.05% or -$0.0742 on its low of $0.4013 reached on 08/09/23. The company’s shares have touched a 52-week low of $0.38 and high of $2.61, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, INO has lost -71.19% or -$1.1139 and has reached a new high 7 times. However, the current price is down -82.78% from the 52-week high price.
Insider Transactions
INO stock investors last saw insider trading activity on Jun 05.Zoth Lota S. (Director) most recently sold 5,700 shares at $0.56 per share on Jun 05. This transaction cost the insider $3,192. Director, Weiner David B., sold 5,833 shares at a price of $1.15 on Mar 13. Then, on Feb 27, Director Weiner David B. sold 11,668 shares at a price of $1.28 per share. This transaction amounted to $14,935.
Valuation Metrics
INO stock has a beta of 0.98. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 12.78 while the price-to-book (PB) in the most recent quarter is 0.70.
Inovio Pharmaceuticals Inc.’s quick ratio for the period ended June 30 was 3.90, with the current ratio over the same period at 3.90. The trailing 12-month EBITDA margin is -2619.08%. The firm’s gross profit as reported stood at $277.84 million against revenue of $10.26 million.
Earnings Surprise
For the quarterly period ending June 30 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -205.38% to -$35.53 million, while revenue of -$40.65 million was -14.41% off the previous quarter. Analysts expected INO to announce -$0.14 per share in earnings in its latest quarter, but it posted -$0.13, representing a 7.10% surprise. EBITDA for the quarter stood at more than -$37.14 million. INO stock balance sheet for the quarter ending June 30 shows that total liabilities totaled 63.67 million, with total debt at $30.76 million. Shareholders hold equity totaling $268.07 million.
Let’s look briefly at Inovio Pharmaceuticals Inc. (INO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 August was 44.69% to suggest the stock is trending Neutral, with historical volatility in this time period at 67.59%.
The stock’s 5-day moving average is $0.4432, reflecting a -0.87% or -$0.0039 change from its current price. INO is currently trading -9.82% above its 20-day SMA, -49.20% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -14.67% and SMA200 by-79.06%.
Stochastic %K and %D was 39.00% and 34.08% and the average true range (ATR) pointed at 0.0340. The RSI (14) points at 43.95%, while the 14-day stochastic is at 46.86% with the period’s ATR at 0.0371. The stock’s 9-day MACD Oscillator is pointing at -0.0055 and -0.0009 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Inovio Pharmaceuticals Inc. (NASDAQ: INO), Maxim Group downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for INO stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate INO as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is INO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $0.50 and a high of $2.00, with their median price target at $1.25. Looking at these predictions, the average price target given by analysts is for Inovio Pharmaceuticals Inc. (INO) stock is $1.25.
